Rocket Pharmaceuticals (RCKT) Stock Statistics & Valuation Metrics

Rocket Pharmaceuticals has a market cap or net worth of $694.91M. The enterprise value is ―.

Rocket Pharmaceuticals has 107,737,920 shares outstanding. The number of shares has decreased by -2.65% in one year.

Rocket Pharmaceuticals’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -55.77%.

The current PE Ratio of Rocket Pharmaceuticals is -4.61. Rocket Pharmaceuticals’s PEG ratio is -3.46.

In the last 12 months, Rocket Pharmaceuticals had revenue of 0.00 and earned -258.75M in profits. Earnings per share was -2.73.

In the last 12 months, operating cash flow was -209.78M and capital expenditures -5.86M, giving a free cash flow of -215.64M billion.

Rocket Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Rocket Pharmaceuticals upcoming earnings date is Aug 11, 2025, TBA Not Confirmed.

Rocket Pharmaceuticals as a current ratio of 9.30, with Debt / Equity ratio of 5.50%

In the past 12 months, Rocket Pharmaceuticals has paid 0.00 in taxes.

Rocket Pharmaceuticals EV to EBITDA ratio is -3.86, with an EV/FCF ratio of -5.02.

Rocket Pharmaceuticals has $372.34M in cash and marketable securities with $25.50M in debt, giving a net cash position of -$346.84M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Rocket Pharmaceuticals is $37.23, which is 11.43% higher than the current price. The consensus rating is Strong Buy